Alain Piché, MD, MSc

Alain Piché has received his B. Sc. in Biochemistry from Université Laval in 1983, and his M.Sc. in Microbiology from Université de Sherbrooke in 1986. After completing his microbiology and infectious diseases training in 1995 at Centre Hospitalier Universitaire de Sherbooke, he pursued a post-doctoral fellowship under the supervision of David T Curiel in the Gene Therapy Program at the University of Alabama in Birmingham with the aim of developing novel gene therapy approaches for the treatment of ovarian cancer. His research efforts focused at understanding the mechanisms ovarian cancer dissemination and progression, and more specifically how the surrounding environment may affect these processes, as well as application in emerging areas, such as the use of cell therapy. His group was the first to demonstrate the therapeutic potential of engineered human mesothelial cells for the treatment of ovarian cancer. He group was also the first to demonstrate the oncogenic properties of Muc16 mucin and its role in enhancing ovarian cancer drug resistance. His work has been supported by grants from the Cancer Research Society, the Canadian Institutes of Health Research and the Terry Fox Research Institute. He currently directs the ovarian and prostate biobanks at Centre de Recherche du CHUS. He also serves as a standing member of the executive committee of the Réseau de Recherche sur le Cancer of FRQS and as associate editor for the American Journal of Cancer Research.

Editorial Board
Terms of Appointment: September 2018 - August 2020;  September 2020 - August 2022